{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:02:21Z","timestamp":1753876941023,"version":"3.41.2"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A computerized drug utilization review (DUR) program has provided physicians and pharmacists with alerts on drug\u2013drug interactions (DDIs), drug\u2013age precautions and therapeutic duplication in Korea since 2010.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The purpose of this study was to evaluate the impact of the DUR program on health outcomes associated with DDIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An uncontrolled before\u2013after study was performed to investigate the impact of the nationwide DUR program on DDIs and related health outcomes. The study population consisted of people who used two types of DDI pairs before DUR implementation (from January 2009 to December 2010) and post-DUR implementation (from January 2012 to December 2013); (i) benzodiazepines with concurrent use of metabolic enzyme inhibitors and (ii) QTc (heart-rate corrected QT interval) prolongation agents. The main outcome measures were all-cause and cause-specific hospitalization admissions or emergency department (ED) visits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 107\u2009874 people who used benzodiazepines with enzyme inhibitors and 8489 who received co-medication of QTc prolongation agents. For patients receiving a combination of benzodiazepines and enzyme inhibitors, both all-cause hospitalization and cause-specific hospitalization decreased after DUR implementation, from 43.2% to 41.7% and from 4.6% to 4.5% (adjusted odds ratio [OR]\u2009=\u20090.96; 95% confidence interval (CI), 0.93\u20130.98; OR\u2009=\u20090.89, 95% CI\u2009=\u20090.84\u20130.99, respectively). For patients receiving co-medication of QTc prolongation agents, all-cause hospitalization (54.2%) was lower than before (54.9%) (OR\u2009=\u20090.87, 95% CI\u2009=\u20090.79\u20130.96), but no significant change was found for cause-specific hospitalization and ED visits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Implementation of a DUR program may reduce the adverse health outcomes posed by DDIs in patients on combination of benzodiazepines and enzyme inhibitors potentially QTc-prolongation agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/intqhc\/mzab118","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:25:07Z","timestamp":1628537107000},"source":"Crossref","is-referenced-by-count":5,"title":["Effect of nationwide concurrent drug utilization review program on drug\u2013drug interactions and related health outcome"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1807","authenticated-orcid":false,"given":"Dong-Sook","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Research, Health Insurance Review and Assessment Service, HyeoksinRo 60, Wonju 26465, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Pusan National University, Pusandaehakro 63Gil 2, Busan 14624, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Research, Health Insurance Review and Assessment Service, HyeoksinRo 60, Wonju 26465, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhyang","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ajou University, WorldcupRo 206, Suwon 16499, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"2022022417490156200_R1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/00005650-199312000-00001","article-title":"Drug utilization review in ambulatory settings: state of the science and directions for outcomes research","volume":"31","author":"Lipton","year":"1993","journal-title":"Med Care"},{"key":"2022022417490156200_R2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"key":"2022022417490156200_R3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18553\/jmcp.2004.10.5.433","article-title":"Current status of prospective drug utilization review","volume":"10","author":"Fulda","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"2022022417490156200_R4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1331\/154434504322713255","article-title":"Medicaid drug utilization review annual reports for federal fiscal year 1999: looking back to move forward","volume":"44","author":"Fulda","year":"2004","journal-title":"J Am Pharm Assoc"},{"article-title":"Alexandria: Academy of Managed Care Pharmacy Available","year":"2019","author":"AMCP. Drug Utilization Review","key":"2022022417490156200_R5"},{"key":"2022022417490156200_R6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4258\/hir.2016.22.1.39","article-title":"New alert override codes for the drug utilization review system derived from outpatient prescription data from a tertiary teaching hospital in Korea","volume":"22","author":"Jang","year":"2016","journal-title":"Healthc Inform Res"},{"key":"2022022417490156200_R7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijmedinf.2013.07.001","article-title":"Evaluation of the pilot program on the real-time drug utilization review system in South Korea","volume":"82","author":"Heo","year":"2013","journal-title":"Int J Med Inform"},{"key":"2022022417490156200_R8","article-title":"Evaluation of preventable adverse drug reactions by implementation of the nationwide network of prospective drug utilization review program in Korea","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"2022022417490156200_R9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ijmedinf.2015.08.007","article-title":"The effect of the introduction of a nationwide DUR system where local DUR systems are operating\u2014the Korean experience","volume":"84","author":"Yang","year":"2015","journal-title":"Int J Med Inform"},{"key":"2022022417490156200_R10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1001\/jama.290.11.1494","article-title":"Retrospective drug utilization review, prescribing errors, and clinical outcomes","volume":"290","author":"Hennessy","year":"2003","journal-title":"JAMA"},{"key":"2022022417490156200_R11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/pds.568","article-title":"Identifying hospital admissions due to adverse drug events using a computer-based monitor","volume":"10","author":"Jha","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022022417490156200_R12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2337\/diacare.23.2.192","article-title":"Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome","volume":"23","author":"Petitti","year":"2000","journal-title":"Diabetes Care"},{"key":"2022022417490156200_R13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/pds.3357","article-title":"Fall risk increasing drugs and injuries of the frail elderly - evidence from administrative data","volume":"21","author":"Bauer","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022022417490156200_R14","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults","volume":"63","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"2022022417490156200_R15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2022022417490156200_R16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1176\/appi.ps.201200089","article-title":"Economic impact of inappropriate benzodiazepine prescribing and related drug interactions among elderly persons","volume":"64","author":"Dionne","year":"2013","journal-title":"Psychiatr Serv"},{"key":"2022022417490156200_R17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.amjopharm.2011.10.006","article-title":"Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study","volume":"10","author":"Chatterjee","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"2022022417490156200_R18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1533-2500.2011.00503.x","article-title":"Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids","volume":"12","author":"Pergolizzi","year":"2012","journal-title":"Pain Pract"},{"volume-title":"Report of the Evaluation for Validity of Discharged Diagnoses in\n            K\n            orean Health Insurance Database","year":"2003","author":"Park","key":"2022022417490156200_R19"},{"volume-title":"National HealthInsurance Statistical Yearbook","year":"2019","author":"HIR","key":"2022022417490156200_R20"},{"key":"2022022417490156200_R21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pds.1287","article-title":"Risk factors for statin-associated rhabdomyolysis","volume":"16","author":"Schech","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022022417490156200_R22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.5414\/CP202375","article-title":"Physicians\u2019 and pharmacists\u2019 acceptance of online, real-time \u201cdrug combinations to avoid\u201d messages","volume":"53","author":"Kim","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2022022417490156200_R23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pds.3487","article-title":"Impact of a drug utilization review program on high-risk use of prescription controlled substances","volume":"23","author":"Daubresse","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022022417490156200_R24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.18553\/jmcp.2003.9.6.513","article-title":"Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population","volume":"9","author":"Peng","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"2022022417490156200_R25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/intqhc\/mzx085","article-title":"Physicians\u2019 and pharmacists\u2019 perceptions on real-time drug utilization review system: a nationwide survey","volume":"29","author":"Lee","year":"2017","journal-title":"Int J Qual Health Care"},{"key":"2022022417490156200_R26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-019-02624-1","article-title":"Can screening tools for potentially inappropriate prescriptions in older adults prevent serious adverse drug events?","volume":"75","author":"Wang-Hansen","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2022022417490156200_R27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3111\/13696998.2011.583302","article-title":"Economic impact of potential drug-drug interactions in opioid analgesics","volume":"14","author":"Summers","year":"2011","journal-title":"J Med Econ"}],"container-title":["International Journal for Quality in Health Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/intqhc\/advance-article-pdf\/doi\/10.1093\/intqhc\/mzab118\/39768168\/mzab118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intqhc\/article-pdf\/33\/3\/mzab118\/42599631\/mzab118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intqhc\/article-pdf\/33\/3\/mzab118\/42599631\/mzab118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T17:51:59Z","timestamp":1645725119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intqhc\/article\/doi\/10.1093\/intqhc\/mzab118\/6353545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/intqhc\/mzab118","relation":{},"ISSN":["1353-4505","1464-3677"],"issn-type":[{"type":"print","value":"1353-4505"},{"type":"electronic","value":"1464-3677"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,7,1]]},"article-number":"mzab118"}}